Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain

References

• Palella FJ Jr, Phair JP. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS. 2011;6:266–271.
   PubMed Web of Science ®Google Scholar
• Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One. 2012;7:e44454.
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Thiebaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17:491–501.
   PubMed Web of Science ®Google Scholar
• D'Agostino RB Sr. Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population. J Infect Dis. 2012;205(Suppl 3):S362–S367.
   PubMed Web of Science ®Google Scholar
• Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366:321–329.
   PubMed Web of Science ®Google Scholar
• Masia M, Perez-Cachafeiro S, Leyes M, et al. Riesgo cardiovascular en pacientes con infección por el virus de la inmunodeficiencia humana en España. Cohorte CoRIS, 2011. Enferm Infecc Microbiol Clin. 2012;30:517–527.
   PubMed Web of Science ®Google Scholar
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III), JAMA. 2001;285:2486–2497.
   PubMed Web of Science ®Google Scholar
• Grau M, Marrugat J. Funciones de riesgo en la prevención primaria de las enfermedades cardiovasculares. Rev Esp Cardiol. 2008;61:404–416.
   PubMed Web of Science ®Google Scholar
• Petr EJ, Ayers CR, Pandey A, et al. Perceived lifetime risk for cardiovascular disease (from the Dallas Heart Study). Am J Cardiol. 2014;114:53–58.
   PubMed Web of Science ®Google Scholar
• Catalina-Romero C, Sainz Gutierrez JC, Quevedo AL, et al. Prevalencia de consumo de tabaco en población trabajadora tras la entrada en vigor de la Ley 42/2010. Rev Esp Salud Publica. 2012;86:177–188.
   PubMed Web of Science ®Google Scholar
• Martinez E, Arribas J, López-Aldeguer J. Factors associated with a high cardiovascular risk in HIV infected patients in Spain: a multicenter, nationwide, cross sectional study. Paper presented at: 12th Conference on Retrovirus and Opportunistic Infections; February 22–25, 2005; Boston, MA, USA. Abs # 870.
   Google Scholar
• Jerico C, Knobel H, Sorli ML, Montero M, Guelar A, Pedro-Botet J. Prevalencia de factores de riesgo cardiovascular en pacientes con infección por el VIH. Rev Clin Esp. 2006;206:556–559.
   PubMed Web of Science ®Google Scholar
• Garcia-Lazaro M, Rivero RA, Camacho EA, et al. Variabilidad en la valoración del riesgo coronario en pacientes infectados por el virus de la inmunodeficiencia humana. Med Clin (Barc). 2007;129:521–524.
   PubMed Web of Science ®Google Scholar
• Franco M, Cooper R, Bilal U, Fuster V. Control of coronary heart disease risk factors and evidence-based therapies: joint efforts for coronary heart disease prevention in Spain. Rev Esp Cardiol. 2011;64:962–964.
   PubMed Web of Science ®Google Scholar
• Huber M, Ledergerber B, Sauter R, et al. Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians. HIV Med. 2012;13:387–397.
   PubMed Web of Science ®Google Scholar
• Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292–2333.
   PubMed Web of Science ®Google Scholar
• Worm SW, Kamara DA, Reiss P, et al. Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS. 2011;25:1497–1504.
   PubMed Web of Science ®Google Scholar
• Freiberg MS, Leaf DA, Goulet JL, et al. The association between the receipt of lipid lowering therapy and HIV status among veterans who met NCEP/ATP III criteria for the receipt of lipid lowering medication. J Gen Intern Med. 2009;24:334–340.
   PubMed Web of Science ®Google Scholar
• Reinsch N, Neuhaus K, Esser S, et al. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur J Prev Cardiol. 2012;19:267–274.
   PubMed Web of Science ®Google Scholar
• Ahmed MH, Al-Atta A, Hamad MA. The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges. Expert Opin Pharmacother. 2012;13:1901–1909.
   PubMed Web of Science ®Google Scholar
• Berry JD, Liu K, Folsom AR, et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the coronary artery risk development in young adults study and multi-ethnic study of atherosclerosis. Circulation. 2009;119:382–389.
   PubMed Web of Science ®Google Scholar
• Hulten E, Villines TC, Cheezum MK, et al. Calcium score, coronary artery disease extent and severity, and clinical outcomes among low Framingham risk patients with low vs high lifetime risk: results from the CONFIRM registry. J Nucl Cardiol. 2014;21:29–37.
   PubMed Web of Science ®Google Scholar
• Marma AK, Lloyd-Jones DM. Systematic examination of the updated Framingham heart study general cardiovascular risk profile. Circulation. 2009;120:384–390.
   PubMed Web of Science ®Google Scholar
• Ferreira-Gonzalez I. The epidemiology of coronary heart disease. Rev Esp Cardiol. 2014;67:139–144.
   PubMed Web of Science ®Google Scholar
• Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Supp 2):S49–73.
   Web of Science ®Google Scholar
• Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26:335–343.
   PubMed Web of Science ®Google Scholar